Trial Profile
A 3 weeks study randomized, multicenter, double blind, vehicle controlled , parallel-group to evaluate the efficacy and safety of Pimecrolimus cream 1% in children between 2 – 11 years with mild to moderate atopic dermatitis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Feb 2015
Price :
$35
*
At a glance
- Drugs Pimecrolimus (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms SPEED
- Sponsors Novartis
- 04 Feb 2015 New trial record